These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 18939498)

  • 41. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
    Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
    J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV CTL escape: at what cost?
    Smith SM
    Retrovirology; 2004 May; 1():8. PubMed ID: 15169568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reversion of CTL escape-variant immunodeficiency viruses in vivo.
    Friedrich TC; Dodds EJ; Yant LJ; Vojnov L; Rudersdorf R; Cullen C; Evans DT; Desrosiers RC; Mothé BR; Sidney J; Sette A; Kunstman K; Wolinsky S; Piatak M; Lifson J; Hughes AL; Wilson N; O'Connor DH; Watkins DI
    Nat Med; 2004 Mar; 10(3):275-81. PubMed ID: 14966520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.
    Kawada M; Igarashi H; Takeda A; Tsukamoto T; Yamamoto H; Dohki S; Takiguchi M; Matano T
    J Virol; 2006 Feb; 80(4):1949-58. PubMed ID: 16439550
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
    Allen TM; O'Connor DH; Jing P; Dzuris JL; Mothé BR; Vogel TU; Dunphy E; Liebl ME; Emerson C; Wilson N; Kunstman KJ; Wang X; Allison DB; Hughes AL; Desrosiers RC; Altman JD; Wolinsky SM; Sette A; Watkins DI
    Nature; 2000 Sep; 407(6802):386-90. PubMed ID: 11014195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Current status of HIV vaccine development].
    Seki S; Matano T
    Nihon Rinsho; 2008 Oct; 66(10):1965-9. PubMed ID: 18939498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 49. HIV and SIV CTL escape: implications for vaccine design.
    Goulder PJ; Watkins DI
    Nat Rev Immunol; 2004 Aug; 4(8):630-40. PubMed ID: 15286729
    [No Abstract]   [Full Text] [Related]  

  • 50. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection.
    Price DA; O'callaghan CA; Whelan JA; Easterbrook PJ; Phillips RE
    Clin Sci (Lond); 1999 Dec; 97(6):707-18. PubMed ID: 10585898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [HIV vaccine].
    Matano T
    Nihon Rinsho; 2005 May; 63 Suppl 5():659-65. PubMed ID: 15954426
    [No Abstract]   [Full Text] [Related]  

  • 53. Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment.
    Wodarz D; Nowak MA
    Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1059-70. PubMed ID: 11186307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. No vaccine against HIV yet--are we not perfectly equipped?
    Singh M
    Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.